Abstract.
A 3-year, open-label, monocenter study was performed on 60 patients with postmenopausal established osteoporosis treated with monofluorophosphate and calcium supplement (MFP/Ca) combined with hormone replacement therapy (HRT). Bone mineral density (BMD) after 3 years increased by 15.5% in the lumbar spine (L2–L4) and by 2.3% in the femur neck. During the 3 years, a total of six new vertebral fractures (NewVF) occurred in five patients (8.3% incidence) and a total of six nonvertebral fractures (Non-VF) occurred in six patients (10% incidence). Back pain score already decreased significantly after 6 months of treatment and, at the end of the 3rd treatment year, the pain score had decreased by 84%. The treatment was well tolerated, with only few mild or moderate adverse events. The results were compared with those of a previous study conducted in the same center with a similar protocol with a calcium supplement on patients suffering from postmenopausal established osteoporosis and treated with MFP/Ca but without HRT. It could be inferred that with the 3-year treatment, the combination of MFP/Ca with HRT protects from NewVF in one patient of every two treated. The comparison suggests that the MFP/Ca with HRT combination could be more effective than MFP/Ca alone in protecting from NewVF and from Non-VF, justifying further double blind, prospective randomized studies pursuing this investigation.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Electronic Publication
Rights and permissions
About this article
Cite this article
Ringe, J., Setnikar, I. Monofluorophosphate combined with hormone replacement therapy in postmenopausal osteoporosis. An open-label pilot efficacy and safety study. Rheumatol Int 22, 27–32 (2002). https://doi.org/10.1007/s00296-002-0193-z
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00296-002-0193-z